We experimentally show that the gain of one of these genes, RBM14, indeed perturbs the DNA damage response and cGAS/STING signaling, and its amplification is associated with increased vulnerability of tumors to radiation treatment in a clinical colorectal cancer cohort. This evidence concerns the gene RBM14 and colorectal cancer.